Hyperbaric Oxygen Therapy on Insulin Resistance in Postmenopause
Background: In postmenopausal females, Insulin resistance is commonly encountered in clinical setting. Hyperbaric oxygen therapy have been proposed effective in lowering blood glucose level and improving function. Identification of clinical examination variables as predictors to blood glucose levels and dysfunction wou
| Condition(s) | Insulin Resistance Syndrome |
|---|---|
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Study type | Interventional |
| Summary | Background: In postmenopausal females, Insulin resistance is commonly encountered in clinical setting. Hyperbaric oxygen therapy have been proposed effective in lowering blood glucose level and improving function. Identification of clinical examination variables as predictors to blood glucose levels and dysfunction would offer therapists the chance to undertake clinical decisions and consequently improve treatment efficiency. Objectives: This Predictive validity, diagnostic study conduct to examine the effect of hyperbaric oxygen therapy on insulin resistance in postmenopausal women. |
| Who can participate | Inclusion Criteria: * A)Inclusion Criteria * All females were clinically diagnosed with Postmenopausal Insulin resistance. * Their ages were ranged from 55-65 years old. * Their BMI was 30-34.9 kg/m². * All patients should had controlled blood glucose levels by oral hypoglycemic drugs. * All patients should had cardiac Ejection Fraction \>or =50%. * Their Chest X-ray reported normal. * Their Ear ,nose , thorax will be clinically evaluated by a specialized ENT physician to ensure fitting for hyperbaric chamber * Voluntary acceptance of participation in the study . B)Exclusion Criteria: Participants will be excluded if they have : * Chronic obstructive pulmonary disease. * Cardiac pacemakers. * Epileptic fits. * Physically disable . * Any disorder that lead to ulcers other than diabetes such |
| Ages | 55 Years to 65 Years |
| Sex | Female |
| Lead sponsor | Cairo University |
| Locations | Cairo, Cairo Governorate, Egypt |
| Start date | 2025-01-28 |
| NCT ID | NCT06806345 |
| Official listing | https://clinicaltrials.gov/study/NCT06806345 |